ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 98,700 shares, a growth of 45.4% from the May 15th total of 67,900 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 55,900 shares, the days-to-cover ratio is presently 1.8 days.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ABVX shares. Guggenheim started coverage on shares of ABIVAX Société Anonyme in a research report on Monday, April 29th. They set a “buy” rating and a $50.00 price objective for the company. Morgan Stanley boosted their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, April 11th. BTIG Research initiated coverage on ABIVAX Société Anonyme in a research report on Monday, May 20th. They set a “buy” rating and a $43.00 price objective for the company. Finally, Piper Sandler began coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued an “overweight” rating and a $42.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.20.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in shares of ABIVAX Société Anonyme during the first quarter worth $81,000. Capstone Investment Advisors LLC acquired a new stake in ABIVAX Société Anonyme during the 4th quarter worth about $618,000. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $642,000. Kennedy Capital Management LLC lifted its stake in shares of ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares during the period. Finally, Rosalind Advisors Inc. bought a new stake in shares of ABIVAX Société Anonyme during the 1st quarter valued at about $5,411,000. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Down 0.3 %

Shares of ABVX opened at $13.58 on Friday. The stock’s 50-day moving average price is $14.44 and its two-hundred day moving average price is $13.10. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.